NASDAQ : SLXN
Silexion Therapeutics Corp — Company profile
Healthcare · Biotechnology · Israel
Last price 0.1452 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 807.35K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
Details
| Name | Silexion Therapeutics Corp |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 14 |
| Founded | 2008 |
| Ceo | Ilan Hadar |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | KYG1281K1489 |
| Cusip | G1281K148 |
| Cik | 2022416 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Ilan Hadar M.B.A. | Chairman and Chief Executive Officer |
| Mirit Horenshtein Hadar | Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific and Development Officer |
Contact
| Address | 12 Abba Hillel Road, Ramat Gan, 5250606, Israel |
| Phone | 972 3 756 4999 |
| Website | https://silexion.com |